Ulcerative colitis

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Aminosalicylates. The original article is from Digestive Diseases and Sciences.

PSC is rare in the general population but substantially more common in people with IBD, particularly ulcerative colitis, and it raises long-term hepatobiliary risks including cholangiocarcinoma—so knowing how often PSC...

Many people worry that medications taken during pregnancy could affect a child’s long-term health. This large study suggests that prenatal use of acid-suppressive drugs is not clearly linked to a meaningful increase in...

an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...

This study quantifies the large NHS and societal costs of Crohn’s disease and ulcerative colitis in the UK and highlights that ongoing management and maintaining remission are major drivers of expense.

Many people with IBD avoid NSAIDs because of flare concerns. This large study suggests prescription NSAIDs did not meaningfully increase hospitalization risk overall, but patients with Crohn disease showed a higher risk....

This study links an HLA gene (DRB1) to shared T cell receptor patterns in both Crohn’s disease and ulcerative colitis, suggesting common immune targets across IBD subtypes. That could help researchers identify antigens...

Cure8 found this source from nbc4i.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full details.

A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...

Cure8 found this source from nbc4i.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full details.

Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis. Open the original article for the full details.

Based on the title and source metadata, this appears to be an event or fundraiser related to Crohn's disease, Ulcerative colitis, and Community and awareness. The original article is from msn.com.

A new national approval means guselkumab (TREMFYA) may soon be an available treatment option for people with Crohn’s disease or ulcerative colitis in Egypt, potentially expanding choices for moderate-to-severe disease....

Cure8 found this source from nbc4i.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Community and awareness. Open the original article for the full details.

Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from uk.style.yahoo.com.

The FDA’s acceptance of Takeda’s sBLA is a regulatory step toward possibly approving IV vedolizumab for children with moderate‑to‑severe UC or Crohn’s. If approved, this would expand an existing adult IBD treatment to...

Cure8 could only read part of this source from contemporarypediatrics.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel...

Cure8 found this source from caledonianrecord.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Vedolizumab. Open the original article for the full details.

This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...

Fibrosis and strictures (fibrostenotic disease) are important unmet problems in Crohn’s disease with limited medical options. An investigational drug that targets PDE4 locally could potentially offer a new approach if...

Cure8 indexed this Crohn's and IBD-related source from syneoshealth.com. It is tagged for Ulcerative colitis, Crohn's disease, and Community and awareness. Open the original article for the full details.

Local walks raise money for research and support services and help reduce stigma by increasing public awareness of Crohn’s disease and ulcerative colitis. Events like this can connect people living with IBD to local...

Cure8 could only read part of this source from thehindu.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from facebook.com.

Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full details.

Cure8 could only read part of this source from cdapress.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.

Spatial transcriptomics helps map where genes are expressed in intestinal tissue, which can reveal cellular mechanisms of IBD and guide research. Knowing which platforms give more reliable data matters for multicenter...

New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Crohn's disease, and Symptoms and flares. The original article is from msn.com.

The article highlights a reported rise in IBD among young people and reinforces that diet and lifestyle factors may influence risk and flare-ups. It reminds readers that IBD symptoms can be mistaken for common...

This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.

Cure8 found this source from channeleye.media, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full...

Stigma is common in people with IBD and can worsen isolation, anxiety, and quality of life. Practical coping strategies and support resources can help reduce emotional burden and improve daily functioning.

Stories like this show real-life challenges people with IBD face (school, work, social life) and point to resources — here, a scholarship — that can reduce financial stress and help people manage health and education.

IBD in children can affect growth, school life, and emotional health, and early recognition reduces risk of complications. Families should know warning signs and that very early‑onset cases may need genetic evaluation...

This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.

IBD affects many parts of life, not just the digestive tract — symptoms, mental health, work and school can all be disrupted. The article highlights support options and a free webinar/guide from a patient advocacy group...

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

This affects people with IBD because it describes late-stage testing decisions for a combination biologic therapy that targets ulcerative colitis and Crohn’s disease. If pursued, the approach could change future...

A book describing a personal recovery from Crohn’s through diet, fitness, and faith may interest people looking for lifestyle approaches or peer experiences. It’s not clinical evidence but could offer practical ideas or...

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. Open the original article for...

This reports Phase 2b results for a new investigational biologic (JNJ-4804) that targets both IL-23 and TNF and showed higher clinical and endoscopic responses in patients with refractory UC and CD — a group with few...

Based on the title and source metadata, this appears to be a conference abstract related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.

New long-term and real-world data about risankizumab and upadacitinib may influence treatment choices and expectations about symptom relief, steroid-sparing effects, treatment persistence, and hospitalization risk for...

Starting college brings new routines, living situations, and social pressures that can affect IBD management. Practical planning around food, medications, stress, and support can help reduce the risk of flares and make...

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Symptoms and flares. The original article is from msn.com.

How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might...

This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.